Your search for apixaban returned 10 results

During extended treatment, bleeding risk was similar for apixaban and rivaroxaban.

No substantial differences seen for other outcomes or for other direct oral anticoagulant comparisons

Apixaban and rivaroxaban are both factor Xa inhibitors.

Significant reductions were seen in dementia risk for rivaroxaban, apixaban, and dabigatran versus warfarin in network meta-analysis

Enrollees in the Medicare prescription drug program paid a total of $3.4 billion in out-of-pocket costs in 2022 for the 10 initial drugs chosen for price negotiations.

Andexxa was granted accelerated approval by the FDA in May 2018.

Risk up with amiodarone vs flecainide or sotalol among seniors with atrial fibrillation receiving apixaban or rivaroxaban.

Asundexian is an investigational oral Factor XIa inhibitor.

Apixaban dominated enoxaparin and edoxaban; rivaroxaban was slightly more effective than apixaban

FDA Panel votes on the potential removal from the market of Makena; results from an apixaban trial of patients with atrial fibrillation and valvular heart disease; reports of serious ocular complications with monkeypox infection; the novavax vaccine becomes the latest authorized COVID-19 booster; and treatments for nephropathy and ALS have their review period extended.